These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 8217542

  • 1. Desferrioxamine and urinary zinc excretion in beta-thalassemia major.
    Uysal Z, Akar N, Kemahli S, Dincer N, Arcasoy A.
    Pediatr Hematol Oncol; 1993; 10(3):257-60. PubMed ID: 8217542
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy.
    Cianciulli P, Sollecito D, Sorrentino F, Forte L, Gilardi E, Massa A, Papa G, Carta S.
    Kidney Int; 1994 Aug; 46(2):467-70. PubMed ID: 7967359
    [Abstract] [Full Text] [Related]

  • 6. Chelation therapy and bone metabolism markers in thalassemia major.
    Pratelli L, Verri E, Fortini M, Marconi S, Zolezzi C, Fornasari PM, Gamberini MR, De Sanctis V.
    J Pediatr Endocrinol Metab; 2006 Nov; 19(11):1335-42. PubMed ID: 17220062
    [Abstract] [Full Text] [Related]

  • 7. The effects of chelators on zinc levels in patients with thalassemia major.
    Erdoğan E, Canatan D, Ormeci AR, Vural H, Aylak F.
    J Trace Elem Med Biol; 2013 Apr; 27(2):109-11. PubMed ID: 23164519
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C.
    Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Growth plate injury of the long bones in treated beta-thalassemia.
    Orzincolo C, Scutellari PN, Castaldi G.
    Skeletal Radiol; 1992 Dec; 21(1):39-44. PubMed ID: 1546335
    [Abstract] [Full Text] [Related]

  • 12. Urinary zinc excretion and zinc status of patients with beta-thalassemia major.
    Aydinok Y, Coker C, Kavakli K, Polat A, Nisli G, Cetiner N, Kantar M, Cetingül N.
    Biol Trace Elem Res; 1999 Nov; 70(2):165-72. PubMed ID: 10535525
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Deferoxamine-induced growth retardation in patients with thalassemia major.
    De Virgiliis S, Congia M, Frau F, Argiolu F, Diana G, Cucca F, Varsi A, Sanna G, Podda G, Fodde M.
    J Pediatr; 1988 Oct; 113(4):661-9. PubMed ID: 3171791
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P, Grady RW, Dragsten P, Vichinsky E, Giardina P, Madden J, Jeng M, Miller B, Hanson G, Hedlund B.
    Br J Haematol; 2007 Aug; 138(3):374-81. PubMed ID: 17614825
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pulmonary embolism and intravenous high-dose desferrioxamine.
    Cianciulli P.
    Haematologica; 1992 Aug; 77(4):368-9. PubMed ID: 1427452
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.